方盛制药(603998.SH)：吲哚布芬片获得《药品注册证书》

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received approval from the National Medical Products Administration for its drug Indobufen tablets, allowing for production [1] Group 1 - The drug Indobufen is an indole butyric acid derivative that acts as a platelet aggregation inhibitor [1]